Kelly Gwathmey is a Neurology physician. OpenAlex indexes 117 publications with 2,217 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
710 W 168th St
New York, NY 100323726
Telephone
212-305-6788Provider last certified this registry record 7 Apr 2026.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20253 payments
- Alexion Pharmaceuticals, Inc.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
79.3%Other nervous system drugs18.1%Radicava Ors100%Part D≥34 patientsGabapentinoids13.7%Gabapentin68%Pregabalin32%Part D≥32 patients+ 11 more classes in this area
Musculoskeletal
8.9%gamma-Aminobutyric Acid-ergic Agonist6.8%Baclofen100%Part D≥28 patientsCentral alpha-2 Adrenergic Agonist2.1%Tizanidine Hcl100%Part D<11 patientsMetabolism & gastrointestinal
6.9%Corticosteroid4.3%Prednisone100%Part D≥16 patientsAnticholinergic1.4%Atropine Sulfate100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases
Expert Review of Clinical Immunology
2025 - <scp>ADAPT NXT</scp>: Fixed Cycles or Every‐Other‐Week <scp>IV</scp> Efgartigimod in Generalized Myasthenia Gravis
Annals of Clinical and Translational Neurology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”